Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 339

1.

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.

Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, van der Heijde D, Winthrop K, Landewé R.

Ann Rheum Dis. 2014 Mar;73(3):529-35. doi: 10.1136/annrheumdis-2013-204575. Review.

PMID:
24401994
2.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D.

Ann Rheum Dis. 2014 Mar;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573.

3.

Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.

Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, Gossec L, Landewe R, Smolen JS, Buch MH.

Ann Rheum Dis. 2014 Mar;73(3):516-28. doi: 10.1136/annrheumdis-2013-204577. Review. Erratum in: Ann Rheum Dis. 2015 Jan;74(1):320.

PMID:
24399231
4.

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.

Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, Bijlsma JW, Burmester GR, Scholte-Voshaar M, Falzon L, Landewé RB.

Ann Rheum Dis. 2017 Mar 15. pii: annrheumdis-2016-210708. doi: 10.1136/annrheumdis-2016-210708. [Epub ahead of print]

PMID:
28298374
5.

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, Worthy G, Landewé R, Smolen JS, Emery P, Buch MH.

Ann Rheum Dis. 2010 Jun;69(6):976-86. doi: 10.1136/ard.2009.126573. Review. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
20447957
6.

Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

Gaujoux-Viala C, Smolen JS, Landewé R, Dougados M, Kvien TK, Mola EM, Scholte-Voshaar M, van Riel P, Gossec L.

Ann Rheum Dis. 2010 Jun;69(6):1004-9. doi: 10.1136/ard.2009.127225. Review.

PMID:
20447954
7.

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis.

Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K, van der Heijde D, Emery P, Smolen JS, Marzo-Ortega H.

Ann Rheum Dis. 2012 Mar;71(3):319-26. doi: 10.1136/ard.2011.150995. Review.

PMID:
21803753
8.

Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.

Kvamme MK, Lie E, Uhlig T, Moger TA, Kvien TK, Kristiansen IS.

Rheumatology (Oxford). 2015 Jul;54(7):1226-35. doi: 10.1093/rheumatology/keu460.

PMID:
25573840
9.

Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.

Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe DJ, Bombardier C.

Cochrane Database Syst Rev. 2016 Aug 29;(8):CD010227. doi: 10.1002/14651858.CD010227.pub2. Review.

PMID:
27571502
10.

Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update.

Singh JA, Cameron DR.

J Manag Care Pharm. 2012 May;18(4 Supp C):S1-18. Review.

PMID:
22656072
11.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JM, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Mar 6. pii: annrheumdis-2016-210715. doi: 10.1136/annrheumdis-2016-210715. [Epub ahead of print]

PMID:
28264816
12.

Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan.

Chiu YM, Lang HC, Lin HY, Yang MT, Fang CH, Yang YW, Schabert VF, Tang B.

Int J Rheum Dis. 2014 Dec;17 Suppl 3:9-19. doi: 10.1111/1756-185X.12539.

PMID:
25496045
13.

Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review.

Roubille C, Haraoui B.

Semin Arthritis Rheum. 2014 Apr;43(5):613-26. doi: 10.1016/j.semarthrit.2013.09.005. Review.

PMID:
24231065
14.

Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.

Baddley JW, Winthrop KL, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR.

Ann Rheum Dis. 2014 Nov;73(11):1942-8. doi: 10.1136/annrheumdis-2013-203407.

15.

Proposal for a new nomenclature of disease-modifying antirheumatic drugs.

Smolen JS, van der Heijde D, Machold KP, Aletaha D, Landewé R.

Ann Rheum Dis. 2014 Jan;73(1):3-5. doi: 10.1136/annrheumdis-2013-204317.

PMID:
24072562
16.

The "dirty little secret" exposed in the 2013 EULAR recommendations for rheumatoid arthritis therapy.

Kissin EY.

Clin Ther. 2014 Jul 1;36(7):1114-6. doi: 10.1016/j.clinthera.2014.06.012.

PMID:
24996488
17.
18.

Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.

Schoels M, Wong J, Scott DL, Zink A, Richards P, Landewé R, Smolen JS, Aletaha D.

Ann Rheum Dis. 2010 Jun;69(6):995-1003. doi: 10.1136/ard.2009.126714. Review.

PMID:
20447950
20.

Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.

Woodworth TG, den Broeder AA.

Best Pract Res Clin Rheumatol. 2015 Aug-Dec;29(4-5):543-9. doi: 10.1016/j.berh.2015.10.001. Review.

PMID:
26697765

Supplemental Content

Support Center